Rocket Pharmaceuticals Inc Stock News

Rocket Pharmaceuticals, Inc. has potential FDA approvals for its gene therapies on the horizon. The company focuses on developing gene therapies for rare diseases, targeting a market that is expected

The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.

EMA accepted Rocket Pharmaceuticals, Inc. regulatory application of RP-L102 for the treatment of patients with Falconi Anemia. A U.S. FDA BLA filing of RP-L102 for the treatment of patients with Falco

Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock?

Rocket Pharmaceuticals, Inc. stock surged 76% post a "Buy" recommendation, fueled by positive Phase 2 trial news for RP-A501 in Danon disease. RP-A501, targeting a rare disease without current treatme

Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.

While investors should probably direct the majority of their market-earmarked funds toward slow-and-steady ideas – à la Warren Buffett – sometimes, we end up with gambling money. And in that case

Rocket (RCKT) gains 40% in three months on positive regulatory updates on its key candidates.

Rocket Pharmaceuticals has two programs approaching commercialization. By contrast, Intellia's candidates won't be ready for quite some time.

Rocket Pharmaceucticals (RCKT) soars 53.8% in a week on news of alignment with the FDA for the mid-stage study of RP-A501, an investigational gene therapy for treating Danon Disease.

Shares of Rocket Pharmaceuticals (NASDAQ: RCKT ) popped sharply higher on Wednesday, making it one of the top-trending tickers. Yesterday, the biotechnology specialist — which focuses on rare childh

The company also announced a public stock offering that it said was worth $175 million. The clinical-stage biotech focuses on genetic therapies for rare diseases.

Rocket Pharmaceuticals reaches alignment with the Food and Drug Administration regarding its global Phase 2 trial for a treatment of Danon disease.

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) stock is soaring today, after the biotech name reached an "alignment" with the U.S. Food & Drug Administration (FDA) regarding a mid-stage trial design for its

Rocket Pharmaceuticals Inc (RCKT) shares surged 32% in pre-market trading on Wednesday after the biotechnology company developing gene therapy announced that it has reached an agreement with the US Fo